24 Poster Discussion - Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC)

Autor: Lin, C.C. 1, Joerger, M. 2, Grell, P. 3, Chiappori, A.A. 4, Leal, T.A. 5, Kasper, S. 6, Jerusalem, G. 7, Gonçalves, A. 8, Wolf, J. 9, De Braud, F. 10, de Jonge, M.J.A. 11, Otero, J. 12, Chhagan, S. 12, Cipolletta, D. 13, Morris, E. 14, Chowdhury, N.R. 15, Hurtado, F.K. 16, Tan, D.S. 17
Zdroj: In European Journal of Cancer October 2020 138 Supplement 2:S12-S13
Databáze: ScienceDirect
Externí odkaz: